Verastem Oncology (VSTM) announced the pricing of an underwritten public offering of 13.33 million shares of its common stock and accompanying warrants to purchase up to 13.33 million shares of its common stock at a combined offering price to the public of $3.00 per share and accompanying warrant.
In lieu of common stock to certain investors, Verastem Oncology offered pre-funded warrants to purchase up to an aggregate of 5 million shares of its common stock and accompanying warrants to purchase up to 5 million shares of its common stock at a combined offering price to the public of $2.999 per pre-funded warrant and accompanying warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.
The warrants have an exercise price of $3.50 per share, are exercisable immediately and will expire 18 months from the date of issuance.
The company expects gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable, to be approximately $55.0 million.
The offering is expected to close on July 25, 2024, subject to customary conditions. All of the securities to be sold in the offering are to be sold by Verastem Oncology.
Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.